Hansa Biopharma AB (publ) (HNSBF)
USD 2.83
(0.0%)
USD 2.83
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 70.95 Million SEK | -40.31% |
| 2022 | 116.04 Million SEK | 528.88% |
| 2021 | 18.45 Million SEK | 261.75% |
| 2020 | 5.1 Million SEK | 104.2% |
| 2019 | 2.49 Million SEK | 2.29% |
| 2018 | 2.44 Million SEK | -24.19% |
| 2017 | 3.22 Million SEK | 36.37% |
| 2016 | 2.36 Million SEK | -50.54% |
| 2015 | 4.77 Million SEK | 6.82% |
| 2014 | 4.47 Million SEK | 217.31% |
| 2013 | 1.4 Million SEK | -72.4% |
| 2012 | 5.1 Million SEK | 1280.67% |
| 2011 | -432.43 Thousand SEK | -109.72% |
| 2010 | 4.44 Million SEK | 49.08% |
| 2009 | 2.98 Million SEK | 2777.99% |
| 2008 | 103.67 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 37.82 Million SEK | 17.15% |
| 2024 Q3 | 37.28 Million SEK | 701.94% |
| 2024 Q2 | -6.19 Million SEK | -116.38% |
| 2023 Q3 | 6.18 Million SEK | -65.54% |
| 2023 Q4 | 32.28 Million SEK | 422.33% |
| 2023 FY | 69.26 Million SEK | -40.31% |
| 2023 Q1 | 14.54 Million SEK | -44.54% |
| 2023 Q2 | 17.93 Million SEK | 23.3% |
| 2022 FY | 116.04 Million SEK | 528.88% |
| 2022 Q2 | 21.32 Million SEK | 11.94% |
| 2022 Q3 | 49.45 Million SEK | 131.93% |
| 2022 Q4 | 26.23 Million SEK | -46.95% |
| 2022 Q1 | 19.04 Million SEK | 61.75% |
| 2021 FY | 18.45 Million SEK | 261.75% |
| 2021 Q4 | 11.77 Million SEK | 522.35% |
| 2021 Q3 | -2.78 Million SEK | -226.61% |
| 2021 Q2 | 2.2 Million SEK | -69.69% |
| 2021 Q1 | 7.26 Million SEK | 98.74% |
| 2020 Q1 | 462 Thousand SEK | -55.7% |
| 2020 FY | 5.1 Million SEK | 104.2% |
| 2020 Q3 | 477 Thousand SEK | -5.92% |
| 2020 Q2 | 507 Thousand SEK | 9.74% |
| 2020 Q4 | 3.65 Million SEK | 666.25% |
| 2019 Q4 | 1.04 Million SEK | 134.91% |
| 2019 FY | 2.49 Million SEK | 2.29% |
| 2019 Q1 | 516 Thousand SEK | -16.91% |
| 2019 Q2 | 495 Thousand SEK | -4.07% |
| 2019 Q3 | 444 Thousand SEK | -10.3% |
| 2018 Q3 | 434 Thousand SEK | -48.88% |
| 2018 Q1 | 538 Thousand SEK | -43.96% |
| 2018 Q2 | 849 Thousand SEK | 57.81% |
| 2018 FY | 2.44 Million SEK | -24.19% |
| 2018 Q4 | 621 Thousand SEK | 43.09% |
| 2017 Q3 | 624 Thousand SEK | -2.5% |
| 2017 Q4 | 960 Thousand SEK | 53.85% |
| 2017 FY | 3.22 Million SEK | 36.37% |
| 2017 Q1 | 997 Thousand SEK | 11.02% |
| 2017 Q2 | 640 Thousand SEK | -35.81% |
| 2016 Q2 | 488 Thousand SEK | 0.0% |
| 2016 Q4 | 898 Thousand SEK | 84.02% |
| 2016 FY | 2.36 Million SEK | -50.54% |
| 2016 Q3 | 488 Thousand SEK | 0.0% |
| 2016 Q1 | 488 Thousand SEK | 478.29% |
| 2015 FY | 4.77 Million SEK | 6.82% |
| 2015 Q4 | -129 Thousand SEK | -124.39% |
| 2015 Q3 | 529 Thousand SEK | 0.0% |
| 2015 Q2 | 529 Thousand SEK | -86.25% |
| 2015 Q1 | 3.84 Million SEK | 18.19% |
| 2014 Q2 | 349 Thousand SEK | -76.05% |
| 2014 Q4 | 3.25 Million SEK | 0.0% |
| 2014 Q1 | 1.45 Million SEK | 198.14% |
| 2014 FY | 4.47 Million SEK | 217.31% |
| 2014 Q3 | - SEK | -100.0% |
| 2013 FY | 1.4 Million SEK | -72.4% |
| 2013 Q2 | -1.89 Million SEK | 0.0% |
| 2013 Q3 | -1.48 Million SEK | 21.64% |
| 2013 Q4 | -1.48 Million SEK | 0.0% |
| 2012 FY | 5.1 Million SEK | 1280.67% |
| 2011 FY | -432.43 Thousand SEK | -109.72% |
| 2010 FY | 4.44 Million SEK | 49.08% |
| 2009 FY | 2.98 Million SEK | 2777.99% |
| 2008 FY | 103.67 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -373.038% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -2287166.28% |
| SQZ Biotechnologies Company | 9.79 Million USD | -624.433% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -506.108% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 40.431% |
| Mesoblast Limited | -35.16 Million USD | 301.749% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 207862.811% |
| Genus plc | 178.7 Million USD | 60.296% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -17198.16% |
| Marizyme, Inc. | 457.7 Thousand USD | -15401.571% |
| ContraFect Corporation | -154 Thousand USD | 46172.078% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 645109.091% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 142002.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -92331.052% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -107846.385% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 18409.888% |
| MultiCell Technologies, Inc. | 49.32 USD | -143858375.264% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -76.21% |
| EV Biologics, Inc. | 48.9 Thousand USD | -144994.07% |
| Q BioMed Inc. | -8988.00 USD | 789496.974% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -151.11% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 460103.89% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 67.765% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -101258.571% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 57202.961% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -113921.47% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 1432874.637% |
| Arch Therapeutics, Inc. | -2439.00 USD | 2909120.09% |
| IMV Inc. | -962.29 Thousand USD | 7473.08% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -50398.932% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 72859.063% |
| GB Sciences, Inc. | -624.00 USD | 11370452.564% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 82574.311% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.062% |
| Halberd Corporation | -208.00 USD | 34111157.692% |
| Enzolytics Inc. | 30.7 Thousand USD | -230950.541% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -5127.968% |
| SYBLEU INC | 11.69 Thousand USD | -606526.197% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -14606.913% |
| argenx SE | 1.1 Billion USD | 93.599% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 375.025% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -11392.199% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 82.676% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 801263.053% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -59.952% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 6315.201% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -7081.413% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -638.227% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 84717.586% |
| BioStem Technologies, Inc. | 15.42 Million USD | -359.979% |
| ONE Bio Corp. | 20.12 Million USD | -252.544% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 599601.479% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 147121.281% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -40085.206% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -40085.206% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 13890.014% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 11359.597% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 244758.621% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -15665.382% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 22306.399% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -1439.735% |
| Bioxytran, Inc. | -8285.00 USD | 856478.998% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 19121.716% |
| Neutra Corp. | 14.33 Thousand USD | -494849.424% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 86625.61% |
| PureTech Health plc | -1.6 Million USD | 4526.138% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 7186.341% |
| IXICO plc | 3.27 Million USD | -2069.755% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 10323.487% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 4061.53% |
| CSL Limited | 7.7 Billion USD | 99.079% |
| Cellectis S.A. | 18 Thousand USD | -394072.222% |